Advertisement
American Journal of Kidney Diseases

β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis

Published:September 30, 2020DOI:https://doi.org/10.1053/j.ajkd.2020.07.023

      Rational & Objective

      Beta-blockers are recommended for patients with heart failure (HF) but their benefit in the dialysis population is uncertain. Beta-blockers are heterogeneous, including with respect to their removal by hemodialysis. We sought to evaluate whether β-blocker use and their dialyzability characteristics were associated with early mortality among patients with chronic kidney disease with HF who transitioned to dialysis.

      Study Design

      Retrospective cohort study.

      Setting & Participants

      Adults patients with chronic kidney disease (aged ≥18 years) and HF who initiated either hemodialysis or peritoneal dialysis during January 1, 2007, to June 30, 2016, within an integrated health system were included.

      Exposures

      Patients were considered treated with β-blockers if they had a quantity of drug dispensed covering the dialysis transition date.

      Outcomes

      All-cause mortality within 6 months and 1 year or hospitalization within 6 months after transition to maintenance dialysis.

      Analytical Approach

      Inverse probability of treatment weights using propensity scores was used to balance covariates between treatment groups. Cox proportional hazard analysis and logistic regression were used to investigate the association between β-blocker use and study outcomes.

      Results

      3,503 patients were included in the study. There were 2,115 (60.4%) patients using β-blockers at transition. Compared with nonusers, the HR for all-cause mortality within 6 months was 0.79 (95% CI, 0.65-0.94) among users of any β-blocker and 0.68 (95% CI, 0.53-0.88) among users of metoprolol at transition. There were no observed differences in all-cause or cardiovascular-related hospitalization.

      Limitations

      The observational nature of our study could not fully account for residual confounding.

      Conclusions

      Beta-blockers were associated with a lower rate of mortality among incident hemodialysis patients with HF. Similar associations were not observed for hospitalizations within the first 6 months following transition to dialysis.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Silverberg D.
        • Wexler D.
        • Blum M.
        • Schwartz D.
        • Iaina A.
        The association between congestive heart failure and chronic renal disease.
        Curr Opin Nephrol Hypertens. 2004; 13: 163-170
        • Sim J.J.
        • Zhou H.
        • Shi J.
        • et al.
        Disparities in early mortality among chronic kidney disease patients who transition to peritoneal dialysis and hemodialysis with and without catheters.
        Int Urol Nephrol. 2018; 50: 963-971
        • Harnett J.D.
        • Foley R.N.
        • Kent G.M.
        • Barre P.E.
        • Murray D.
        • Parfrey P.S.
        Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.
        Kidney Int. 1995; 47: 884-890
        • Wang A.Y.
        • Wang M.
        • Lam C.W.
        • Chan I.H.
        • Lui S.F.
        • Sanderson J.E.
        Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis.
        Clin J Am Soc Nephrol. 2011; 6: 805-812
        • Saran R.
        • Robinson B.
        • Abbott K.C.
        • et al.
        US Renal Data System 2017 Annual Data Report: epidemiology of kidney disease in the United States.
        Am J Kidney Dis. 2018; 71: S1-S676
        • Hjalmarson A.
        • Goldstein S.
        • Fagerberg B.
        • et al.
        Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
        JAMA. 2000; 283: 1295-1302
        • Shah R.U.
        • Chang T.I.
        • Fonarow G.C.
        Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease.
        Heart Fail Clin. 2013; 9: 79-92
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
        J Am Coll Cardiol. 2017; 70: 776-803
        • Shlipak M.G.
        • Browner W.S.
        • Noguchi H.
        • Massie B.
        • Frances C.D.
        • McClellan M.
        Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction.
        Am J Med. 2001; 110: 425-433
        • Agarwal R.
        • Sinha A.D.
        • Pappas M.K.
        • Abraham T.N.
        • Tegegne G.G.
        Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.
        Nephrol Dial Transplant. 2014; 29: 672-681
        • Cice G.
        • Ferrara L.
        • D’Andrea A.
        • et al.
        Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial.
        J Am Coll Cardiol. 2003; 41: 1438-1444
        • Cnossen T.T.
        • Kooman J.P.
        • Konings C.J.
        • Uszko-Lencer N.H.
        • Leunissen K.M.
        • van der Sande F.M.
        Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure.
        Blood Purif. 2010; 30: 146-152
        • Cairns K.B.
        • Porter G.A.
        • Kloster F.E.
        • Bristow J.D.
        • Griswold H.E.
        Clinical and hemodynamic results of peritoneal dialysis for severe cardiac failure.
        Am Heart J. 1968; 76: 227-234
        • Courivaud C.
        • Kazory A.
        • Crépin T.
        • et al.
        Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics.
        Perit Dial Int. 2014; 34: 100-108
        • Stegmayr B.G.
        • Banga R.
        • Lundberg L.
        • Wikdahl A.M.
        • Plum-Wirell M.
        PD treatment for severe congestive heart failure.
        Perit Dial Int. 1996; 16: S231-S235
        • Tang Y.
        • Brooks J.M.
        • Wetmore J.B.
        • Shireman T.I.
        Association between higher rates of cardioprotective drug use and survival in patients on dialysis.
        Res Social Adm Pharm. 2015; 11: 824-843
        • Segall L.
        • Nistor I.
        • Covic A.
        Heart failure in patients with chronic kidney disease: a systematic integrative review.
        Biomed Res Int. 2014; 2014: 937398
        • Badve S.V.
        • Roberts M.A.
        • Hawley C.M.
        • et al.
        Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis.
        J Am Coll Cardiol. 2011; 58: 1152-1161
        • Lee M.S.
        • Zhou H.
        • Shaw S.F.
        • et al.
        Beta-blocker practice patterns in chronic kidney disease patients with atrial fibrillation transitioning to hemodialysis.
        Hemodial Int. 2019; 23: 506-509
        • Poirier L.
        • Tobe S.W.
        Contemporary use of β-blockers: clinical relevance of subclassification.
        Can J Cardiol. 2014; 30: S9-S15
        • Niedermayer W.
        • Seiler K.U.
        • Wassermann O.
        Pharmacokinetics of antihypertensive drugs (atenolol, metoprolol, propranolol and clonidine) and their metabolites during intermittent haemodialysis in humans.
        Proc Eur Dial Transplant Assoc. 1978; 15: 607-609
        • Tieu A.
        • Velenosi T.J.
        • Kucey A.S.
        • Weir M.A.
        • Urquhart B.L.
        β-Blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial.
        Clin J Am Soc Nephrol. 2018; 13: 604-611
        • Weir M.A.
        • Dixon S.N.
        • Fleet J.L.
        • et al.
        β-Blocker dialyzability and mortality in older patients receiving hemodialysis.
        J Am Soc Nephrol. 2015; 26: 987-996
        • Assimon M.M.
        • Brookhart M.A.
        • Fine J.P.
        • Heiss G.
        • Layton J.B.
        • Flythe J.E.
        A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis.
        Am J Kidney Dis. 2018; 72: 337-348
        • Sim J.J.
        • Zhou H.
        • Bhandari S.
        • et al.
        Low systolic blood pressure from treatment and association with serious falls/syncope.
        Am J Prev Med. 2018; 55: 488-496
        • Sim J.J.
        • Handler J.
        • Jacobsen S.J.
        • Kanter M.H.
        Systemic implementation strategies to improve hypertension: the Kaiser Permanente Southern California experience.
        Can J Cardiol. 2014; 30: 544-552
        • Koebnick C.
        Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.
        The Permanente Journal. 2012; : 37-41
        • Xie F.
        • Zheng C.
        • Yuh-Jer Shen A.
        • Chen W.
        Extracting and analyzing ejection fraction values from electronic echocardiography reports in a large health maintenance organization.
        Health Informatics J. 2017; 23: 319-328
        • Austin P.C.
        • Stuart E.A.
        Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.
        Stat Med. 2015; 34: 3661-3679
        • Xu S.
        • Ross C.
        • Raebel M.A.
        • Shetterly S.
        • Blanchette C.
        • Smith D.
        Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals.
        Value Health. 2010; 13: 273-277
        • Jacob C.
        (Statistical Power Analysis for the Behavioral Sciences)2nd ed. Erlbaum, 1988
        • Austin P.C.
        Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research.
        Commun Stat Simul Comput. 2009; 38: 1228-1234
        • Saran R.
        • Robinson B.
        • Abbott K.C.
        • et al.
        US Renal Data System 2018 Annual Data Report: epidemiology of kidney disease in the United States.
        Am J Kidney Dis. 2019; 73: A7-A8
        • Naylor K.L.
        • Kim S.J.
        • McArthur E.
        • Garg A.X.
        • McCallum M.K.
        • Knoll G.A.
        Mortality in incident maintenance dialysis patients versus incident solid organ cancer patients: a population-based cohort.
        Am J Kidney Dis. 2019; 73: 765-776
        • Jin J.
        • Guo X.
        • Yu Q.
        Effects of beta-blockers on cardiovascular events and mortality in dialysis patients: a systematic review and meta-analysis.
        Blood Purif. 2019; 48: 51-59
        • Matsue Y.
        • Suzuki M.
        • Nagahori W.
        • Ohno M.
        • Matsumura A.
        • Hashimoto Y.
        β-Blocker prevents sudden cardiac death in patients with hemodialysis.
        Int J Cardiol. 2013; 165: 519-522
        • Cice G.
        • Ferrara L.
        • Di Benedetto A.
        • et al.
        Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial.
        J Am Coll Cardiol. 2001; 37: 407-411
        • Kitchlu A.
        • Clemens K.
        • Gomes T.
        • et al.
        Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada.
        Nephrol Dial Transplant. 2012; 27: 1591-1598
        • Tang C.H.
        • Wang C.C.
        • Chen T.H.
        • Hong C.Y.
        • Sue Y.M.
        Prognostic benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release in hemodialysis patients with heart failure: a 10-year cohort.
        J Am Heart Assoc. 2016; 5: e002584
        • Fellström B.C.
        • Jardine A.G.
        • Schmieder R.E.
        • et al.
        Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
        N Engl J Med. 2009; 360: 1395-1407
        • Wanner C.
        • Krane V.
        • März W.
        • et al.
        Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
        N Engl J Med. 2005; 353: 238-248
        • Jukema J.W.
        • Timal R.J.
        • Rotmans J.I.
        • et al.
        Prophylactic use of implantable cardioverter-defibrillators in the prevention of sudden cardiac death in dialysis patients.
        Circulation. 2019; 139: 2628-2638
        • Khan F.
        • Adelstein E.
        • Saba S.
        Implantable cardioverter defibrillators confer survival benefit in patients with renal insufficiency but not in dialysis-dependent patients.
        J Interv Card Electrophysiol. 2010; 28: 117-123
        • Gress T.W.
        • Nieto F.J.
        • Shahar E.
        • Wofford M.R.
        • Brancati F.L.
        Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.
        N Engl J Med. 2000; 342: 905-912
        • Bangalore S.
        • Parkar S.
        • Grossman E.
        • Messerli F.H.
        A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus.
        Am J Cardiol. 2007; 100: 1254-1262
        • Hamad A.
        • Salameh M.
        • Zihlif M.
        • Feinfeld D.A.
        • Carvounis C.P.
        Life-threatening hyperkalemia after intravenous labetolol injection for hypertensive emergency in a hemodialysis patient.
        Am J Nephrol. 2001; 21: 241-244
        • McQuillan R.F.
        • Chan C.T.
        The intuitive case for β-blockers in patients with ESRD.
        Semin Dial. 2012; 25: 15-21
        • Weir M.A.
        • Herzog C.A.
        Beta blockers in patients with end-stage renal disease-Evidence-based recommendations.
        Semin Dial. 2018; 31: 219-225
        • Makar M.S.
        • Pun P.H.
        Sudden cardiac death among hemodialysis patients.
        Am J Kidney Dis. 2017; 69: 684-695
        • Aggarwal A.
        • Wang Y.
        • Rumsfeld J.S.
        • Curtis J.P.
        • Heidenreich P.A.
        • National Cardiovascular Data Registry
        Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation.
        Heart Rhythm. 2009; 6: 1565-1571